So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted and present in the US'.

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Pharmaceutical CEOs are on notice about sky-high drug prices as President Donald Trump demands a recalibration of what ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly transferring manufacturing” across the Atlantic.

CNBC's Sara Eisen talks with AstraZeneca Pascal Soriot CEO to discuss the company's most recent quarter, investment in innovation in the U.S., whether tariffs could impact prices, and much more.

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US. Chief Executive Officer Pascal Soriot has ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...